{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T10:58:00Z","timestamp":1768561080961,"version":"3.49.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1124\/dmd.118.084657","type":"journal-article","created":{"date-parts":[[2018,11,12]],"date-time":"2018-11-12T15:05:25Z","timestamp":1542035125000},"page":"67-70","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Identification of 19-(S\/R)Hydroxyeicosatetraenoic Acid as the First Endogenous Noncompetitive Inhibitor of Cytochrome P450 1B1 with Enantioselective Activity"],"prefix":"10.1016","volume":"47","author":[{"given":"Sherif M.","family":"Shoieb","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8692-0400","authenticated-orcid":false,"given":"Ahmed A.","family":"El-Sherbeni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayman O.S.","family":"El-Kadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.118.084657_bib1","doi-asserted-by":"crossref","first-page":"2842","DOI":"10.1016\/j.bmc.2011.03.042","article-title":"Comparative CYP1A1 and CYP1B1 substrate and inhibitor profile of dietary flavonoids","volume":"19","author":"Androutsopoulos","year":"2011","journal-title":"Bioorg Med Chem"},{"key":"10.1124\/dmd.118.084657_bib2","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.cbi.2016.07.001","article-title":"Enantioselective inhibition of cytochrome P450-mediated drug metabolism by a novel antithrombotic agent, S002-333: major effect on CYP2B6","volume":"256","author":"Bhateria","year":"2016","journal-title":"Chem Biol Interact"},{"key":"10.1124\/dmd.118.084657_bib3","doi-asserted-by":"crossref","first-page":"39087","DOI":"10.18632\/oncotarget.16598","article-title":"Cytochrome P450 1B1 inhibition suppresses tumorigenicity of prostate cancer via caspase-1 activation","volume":"8","author":"Chang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1124\/dmd.118.084657_bib4","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1139\/y00-067","article-title":"Trans-resveratrol modulates the catalytic activity and mRNA expression of the procarcinogen-activating human cytochrome P450 1B1","volume":"78","author":"Chang","year":"2000","journal-title":"Can J Physiol Pharmacol"},{"key":"10.1124\/dmd.118.084657_bib5","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.tox.2005.09.010","article-title":"Inhibition of human cytochrome CYP 1 enzymes by flavonoids of St. John\u2019s wort","volume":"217","author":"Chaudhary","year":"2006","journal-title":"Toxicology"},{"key":"10.1124\/dmd.118.084657_bib6","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1124\/dmd.32.8.840","article-title":"Metabolism of retinoids and arachidonic acid by human and mouse cytochrome P450 1b1","volume":"32","author":"Choudhary","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.118.084657_bib7","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.toxlet.2009.05.005","article-title":"Potent inhibition of human cytochrome P450 1B1 by tetramethoxystilbene","volume":"189","author":"Chun","year":"2009","journal-title":"Toxicol Lett"},{"key":"10.1124\/dmd.118.084657_bib8","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1080\/09537100902849836","article-title":"Platelets arachidonic acid metabolism in patients with essential hypertension","volume":"20","author":"Do\u0142egowska","year":"2009","journal-title":"Platelets"},{"key":"10.1124\/dmd.118.084657_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ctrv.2017.10.013","article-title":"Cancer chemoprevention revisited: cytochrome P450 family 1B1 as a target in the tumor and the microenvironment","volume":"63","author":"D\u2019Uva","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"10.1124\/dmd.118.084657_bib10","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.bcp.2013.11.015","article-title":"Alterations in cytochrome P450-derived arachidonic acid metabolism during pressure overload-induced cardiac hypertrophy","volume":"87","author":"El-Sherbeni","year":"2014","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.118.084657_bib11","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1124\/dmd.114.057836","article-title":"Characterization of arachidonic acid metabolism by rat cytochrome P450 enzymes: the involvement of CYP1As","volume":"42","author":"El-Sherbeni","year":"2014","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.118.084657_bib12","doi-asserted-by":"crossref","first-page":"893","DOI":"10.2174\/1389200216666150206130058","article-title":"CYP1B1: a unique gene with unique characteristics","volume":"15","author":"Faiq","year":"2014","journal-title":"Curr Drug Metab"},{"key":"10.1124\/dmd.118.084657_bib13","first-page":"527","article-title":"Cytochrome P450 1B1 (CYP1B1) is overexpressed in human colon adenocarcinomas relative to normal colon: implications for drug development","volume":"2","author":"Gibson","year":"2003","journal-title":"Mol Cancer Ther"},{"key":"10.1124\/dmd.118.084657_bib14","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1161\/HYPERTENSIONAHA.110.154518","article-title":"Cytochrome P450 1B1 contributes to angiotensin II-induced hypertension and associated pathophysiology","volume":"56","author":"Jennings","year":"2010","journal-title":"Hypertension"},{"key":"10.1124\/dmd.118.084657_bib15","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1084\/jem.20082596","article-title":"Cardiac 12\/15 lipoxygenase-induced inflammation is involved in heart failure","volume":"206","author":"Kayama","year":"2009","journal-title":"J Exp Med"},{"key":"10.1124\/dmd.118.084657_bib16","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.tox.2014.11.007","article-title":"Cytochrome P1B1 (CYP1B1) polymorphisms and cancer risk: a meta-analysis of 52 studies","volume":"327","author":"Li","year":"2015","journal-title":"Toxicology"},{"key":"10.1124\/dmd.118.084657_bib17","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.pharmthera.2017.03.007","article-title":"Potential role of CYP1B1 in the development and treatment of metabolic diseases","volume":"178","author":"Li","year":"2017","journal-title":"Pharmacol Ther"},{"key":"10.1124\/dmd.118.084657_bib18","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s11010-017-2943-y","article-title":"The role of cytochrome P450 1B1 and its associated mid-chain hydroxyeicosatetraenoic acid metabolites in the development of cardiac hypertrophy induced by isoproterenol","volume":"429","author":"Maayah","year":"2017","journal-title":"Mol Cell Biochem"},{"key":"10.1124\/dmd.118.084657_bib19","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s00204-014-1419-z","article-title":"5-, 12- and 15-Hydroxyeicosatetraenoic acids induce cellular hypertrophy in the human ventricular cardiomyocyte, RL-14 cell line, through MAPK- and NF-\u03baB-dependent mechanism","volume":"90","author":"Maayah","year":"2016","journal-title":"Arch Toxicol"},{"key":"10.1124\/dmd.118.084657_bib20","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/mnfr.200600135","article-title":"Inhibition of human recombinant cytochromes P450 CYP1A1 and CYP1B1 by trans-resveratrol methyl ethers","volume":"51","author":"Mikstacka","year":"2007","journal-title":"Mol Nutr Food Res"},{"key":"10.1124\/dmd.118.084657_bib21","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1161\/HYPERTENSIONAHA.117.09175","article-title":"2-Methoxyestradiol reduces angiotensin II-induced hypertension and renal dysfunction in ovariectomized female and intact male mice","volume":"69","author":"Pingili","year":"2017","journal-title":"Hypertension"},{"key":"10.1124\/dmd.118.084657_bib22","first-page":"617","article-title":"Oxidation of xenobiotics by recombinant human cytochrome P450 1B1","volume":"25","author":"Shimada","year":"1997","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.118.084657_bib23","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1124\/dmd.118.082073","article-title":"S-Enantiomer of 19-hydroxyeicosatetraenoic acid preferentially protects against angiotensin II-induced cardiac hypertrophy","volume":"46","author":"Shoieb","year":"2018","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.118.084657_bib24","doi-asserted-by":"crossref","first-page":"5793","DOI":"10.1158\/1078-0432.CCR-04-2545","article-title":"Cytochrome P450 1B1 is overexpressed and regulated by hypomethylation in prostate cancer","volume":"11","author":"Tokizane","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1124\/dmd.118.084657_bib25","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1158\/0008-5472.CAN-04-0166","article-title":"Human CYP1B1 is regulated by estradiol via estrogen receptor","volume":"64","author":"Tsuchiya","year":"2004","journal-title":"Cancer Res"},{"key":"10.1124\/dmd.118.084657_bib26","first-page":"50","article-title":"Natural cancer therapy and prevention targeted on cancer cells and cancer stem cells based on the cytochrome P45O enzyme CYP1B1: a commentary","volume":"23","author":"Ware","year":"2017","journal-title":"Altern Ther Health Med"},{"key":"10.1124\/dmd.118.084657_bib27","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1161\/HYPERTENSIONAHA.110.150029","article-title":"Angiotensin II-induced vascular smooth muscle cell migration and growth are mediated by cytochrome P450 1B1-dependent superoxide generation","volume":"55","author":"Yaghini","year":"2010","journal-title":"Hypertension"},{"key":"10.1124\/dmd.118.084657_bib28","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/jcp.24443","article-title":"15-LO\/15-HETE mediated vascular adventitia fibrosis via p38 MAPK-dependent TGF-\u03b2","volume":"229","author":"Zhang","year":"2014","journal-title":"J Cell Physiol"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624080899?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624080899?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.118.084657","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T19:05:46Z","timestamp":1739905546000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624080899"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["S0090955624080899"],"URL":"https:\/\/doi.org\/10.1124\/dmd.118.084657","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification of 19-(S\/R)Hydroxyeicosatetraenoic Acid as the First Endogenous Noncompetitive Inhibitor of Cytochrome P450 1B1 with Enantioselective Activity","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.118.084657","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}